{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T17:24:41Z","timestamp":1791998681575,"version":"4.4.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T00:00:00Z","timestamp":1771545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T00:00:00Z","timestamp":1774569600000},"content-version":"vor","delay-in-days":35,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"National High Level Hospital Clinical Research Funding"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardio-Oncology"],"DOI":"10.1186\/s40959-026-00455-5","type":"journal-article","created":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T02:45:29Z","timestamp":1771555529000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Electrocardiographic predictors of major adverse cardiovascular events in immune checkpoint inhibitor\u2013associated myocarditis"],"prefix":"10.1186","volume":"12","author":[{"given":"Kanghao","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangcheng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,20]]},"reference":[{"issue":"4","key":"455_CR1","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1038\/nrd.2015.35","volume":"15","author":"A Hoos","year":"2016","unstructured":"Hoos A. Development of immuno-oncology drugs - from CTLA4 to PD1 to the next generations [J]. Nat Rev Drug Discov. 2016;15(4):235\u201347. https:\/\/doi.org\/10.1038\/nrd.2015.35.","journal-title":"Nat Rev Drug Discov"},{"issue":"12","key":"455_CR2","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","volume":"4","author":"DY Wang","year":"2018","unstructured":"Wang DY, Salem JE, Cohen JV, et al. Fatal toxic effects associated with immune checkpoint inhibitors: A systematic review and Meta-analysis [J]. JAMA Oncol. 2018;4(12):1721\u20138. https:\/\/doi.org\/10.1001\/jamaoncol.2018.3923.","journal-title":"JAMA Oncol"},{"issue":"10","key":"455_CR3","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1111\/jcpt.13707","volume":"47","author":"F Wang","year":"2022","unstructured":"Wang F, Wu X. Cardiovascular toxicities associated with immune checkpoint inhibitors: an updated comprehensive disproportionality analysis of the FDA adverse event reporting system [J]. J Clin Pharm Ther. 2022;47(10):1576\u201384. https:\/\/doi.org\/10.1111\/jcpt.13707.","journal-title":"J Clin Pharm Ther"},{"issue":"16","key":"455_CR4","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1016\/j.jacc.2018.02.037","volume":"71","author":"SS Mahmood","year":"2018","unstructured":"Mahmood SS, Fradley MG, Cohen JV, et al. Myocarditis in patients treated with immune checkpoint inhibitors [J]. J Am Coll Cardiol. 2018;71(16):1755\u201364. https:\/\/doi.org\/10.1016\/j.jacc.2018.02.037.","journal-title":"J Am Coll Cardiol"},{"issue":"10124","key":"455_CR5","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1016\/S0140-6736(18)30533-6","volume":"391","author":"JJ Moslehi","year":"2018","unstructured":"Moslehi JJ, Salem JE, Sosman JA, et al. Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis [J]. Lancet. 2018;391(10124):933. https:\/\/doi.org\/10.1016\/S0140-6736(18)30533-6.","journal-title":"Lancet"},{"issue":"3","key":"455_CR6","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s11886-017-0835-0","volume":"19","author":"DY Wang","year":"2017","unstructured":"Wang DY, Okoye GD, Neilan TG, et al. Cardiovascular toxicities associated with cancer immunotherapies [J]. Curr Cardiol Rep. 2017;19(3):21. https:\/\/doi.org\/10.1007\/s11886-017-0835-0.","journal-title":"Curr Cardiol Rep"},{"issue":"12","key":"455_CR7","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1016\/j.annonc.2022.10.001","volume":"33","author":"J Haanen","year":"2022","unstructured":"Haanen J, Obeid M, Spain L, et al. Management of toxicities from immunotherapy: ESMO clinical practice guideline for diagnosis, treatment and follow-up [J]. Ann Oncol. 2022;33(12):1217\u201338. https:\/\/doi.org\/10.1016\/j.annonc.2022.10.001.","journal-title":"Ann Oncol"},{"issue":"2","key":"455_CR8","doi-asserted-by":"publisher","first-page":"101478","DOI":"10.1016\/j.cpcardiol.2022.101478","volume":"48","author":"W Song","year":"2023","unstructured":"Song W, Zheng Y, Dong M, et al. Electrocardiographic features of immune checkpoint Inhibitor-Associated myocarditis [J]. Curr Probl Cardiol. 2023;48(2):101478. https:\/\/doi.org\/10.1016\/j.cpcardiol.2022.101478.","journal-title":"Curr Probl Cardiol"},{"key":"455_CR9","doi-asserted-by":"publisher","unstructured":"Zlotoff DA, Hassan MZO, Zafar A, et al. Electrocardiographic features of immune checkpoint inhibitor associated myocarditis. J Immunother Cancer. 2021;9(3). https:\/\/doi.org\/10.1136\/jitc-2020-002007.","DOI":"10.1136\/jitc-2020-002007"},{"issue":"15","key":"455_CR10","doi-asserted-by":"publisher","first-page":"e7460","DOI":"10.1002\/cam4.7460","volume":"13","author":"Y Gao","year":"2024","unstructured":"Gao Y, Zhang H, Qiu Y, et al. Early identification of severe immune checkpoint inhibitor associated myocarditis: from an electrocardiographic perspective [J]. Cancer Med. 2024;13(15):e7460. https:\/\/doi.org\/10.1002\/cam4.7460.","journal-title":"Cancer Med"},{"issue":"4","key":"455_CR11","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1093\/eurheartj\/ehab674","volume":"43","author":"J Herrmann","year":"2022","unstructured":"Herrmann J, Lenihan D, Armenian S, et al. Defining cardiovascular toxicities of cancer therapies: an international Cardio-Oncology society (IC-OS) consensus statement [J]. Eur Heart J. 2022;43(4):280\u201399. https:\/\/doi.org\/10.1093\/eurheartj\/ehab674.","journal-title":"Eur Heart J"},{"issue":"3","key":"455_CR12","doi-asserted-by":"publisher","first-page":"230","DOI":"10.6004\/jnccn.2020.0012","volume":"18","author":"JA Thompson","year":"2020","unstructured":"Thompson JA, Schneider BJ, Brahmer J, et al. NCCN guidelines insights: management of Immunotherapy-Related Toxicities, version 1.2020 [J]. J Natl Compr Canc Netw. 2020;18(3):230\u201341. https:\/\/doi.org\/10.6004\/jnccn.2020.0012.","journal-title":"J Natl Compr Canc Netw"},{"issue":"11","key":"455_CR13","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1016\/j.jacc.2008.12.013","volume":"53","author":"B Surawicz","year":"2009","unstructured":"Surawicz B, Childers R, Deal BJ, et al. AHA\/ACCF\/HRS recommendations for the standardization and interpretation of the electrocardiogram: part III: intraventricular conduction disturbances: a scientific statement from the American heart association electrocardiography and arrhythmias Committee, Council on clinical cardiology; the American college of cardiology Foundation; and the heart rhythm society. Endorsed by the international society for computerized electrocardiology [J]. J Am Coll Cardiol. 2009;53(11):976\u201381. https:\/\/doi.org\/10.1016\/j.jacc.2008.12.013.","journal-title":"J Am Coll Cardiol"},{"key":"455_CR14","unstructured":"Food D, Administration HHS. International conference on harmonisation; guidance on E14 clinical evaluation of QT\/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs; availability. Notice. Fed Regist. 2005;70(202):61134\u201361135."},{"key":"455_CR15","doi-asserted-by":"publisher","unstructured":"Rautaharju PM, Surawicz B, Gettes LS, Council on Clinical Cardiology. AHA\/ACCF\/HRS recommendations for the standardization and interpretation of the electrocardiogram: part IV: the ST segment, T and U waves, and the QT interval: a scientific statement from the American Heart Association Electrocardiography and Arrhythmias Committee, ; The American College of Cardiology Foundation; and the Heart Rhythm Society. Endorsed by the International Society for Computerized Electrocardiology. J Am Coll Cardiol, 2009, 53(11): 982\u2013991. https:\/\/doi.org\/10.1016\/j.jacc.2008.12.014.","DOI":"10.1016\/j.jacc.2008.12.014"},{"issue":"18","key":"455_CR16","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1161\/CIRCULATIONAHA.121.055816","volume":"144","author":"JR Power","year":"2021","unstructured":"Power JR, Alexandre J, Choudhary A, et al. Electrocardiographic manifestations of immune checkpoint inhibitor myocarditis [J]. Circulation. 2021;144(18):1521\u20133. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.121.055816.","journal-title":"Circulation"},{"key":"455_CR17","doi-asserted-by":"publisher","first-page":"153779","DOI":"10.1016\/j.jelectrocard.2024.153779","volume":"86","author":"W Song","year":"2024","unstructured":"Song W, Chen Z, Zheng Y, et al. Clinical and electrocardiographic characteristics of immune checkpoint inhibitor-related myocarditis [J]. J Electrocardiol. 2024;86:153779. https:\/\/doi.org\/10.1016\/j.jelectrocard.2024.153779.","journal-title":"J Electrocardiol"},{"key":"455_CR18","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2025.3983","author":"YS Liu","year":"2025","unstructured":"Liu YS, Tan SCW, Zhao YT. A mysterious ST elevation [J]. JAMA Intern Med. 2025. https:\/\/doi.org\/10.1001\/jamainternmed.2025.3983.","journal-title":"JAMA Intern Med"},{"issue":"19","key":"455_CR19","doi-asserted-by":"publisher","first-page":"2867","DOI":"10.2169\/internalmedicine.9161-21","volume":"61","author":"K Naganuma","year":"2022","unstructured":"Naganuma K, Horita Y, Matsuo K, et al. An autopsy case of Late-onset fulminant myocarditis induced by nivolumab in gastric cancer [J]. Intern Med. 2022;61(19):2867\u201371. https:\/\/doi.org\/10.2169\/internalmedicine.9161-21.","journal-title":"Intern Med"},{"issue":"18","key":"455_CR20","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1056\/NEJMoa1609214","volume":"375","author":"DB Johnson","year":"2016","unstructured":"Johnson DB, Balko JM, Compton ML, et al. Fulminant myocarditis with combination immune checkpoint Blockade [J]. N Engl J Med. 2016;375(18):1749\u201355. https:\/\/doi.org\/10.1056\/NEJMoa1609214.","journal-title":"N Engl J Med"},{"issue":"7","key":"455_CR21","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1097\/CJI.0000000000000239","volume":"41","author":"V Jain","year":"2018","unstructured":"Jain V, Mohebtash M, Rodrigo ME, et al. Autoimmune myocarditis caused by immune checkpoint inhibitors treated with antithymocyte Globulin [J]. J Immunother. 2018;41(7):332\u20135. https:\/\/doi.org\/10.1097\/CJI.0000000000000239.","journal-title":"J Immunother"},{"issue":"5","key":"455_CR22","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1093\/cvr\/cvz026","volume":"115","author":"JR Hu","year":"2019","unstructured":"Hu JR, Florido R, Lipson EJ, et al. Cardiovascular toxicities associated with immune checkpoint inhibitors [J]. Cardiovasc Res. 2019;115(5):854\u201368. https:\/\/doi.org\/10.1093\/cvr\/cvz026.","journal-title":"Cardiovasc Res"},{"issue":"6","key":"455_CR23","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1001\/jamainternmed.2022.1226","volume":"182","author":"Y Xu","year":"2022","unstructured":"Xu Y, Hong L, Liu T. Ominous electrocardiographic abnormalities in a patient with hepatocellular carcinoma [J]. JAMA Intern Med. 2022;182(6):674\u20135. https:\/\/doi.org\/10.1001\/jamainternmed.2022.1226.","journal-title":"JAMA Intern Med"},{"issue":"12","key":"455_CR24","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1038\/s41577-018-0065-8","volume":"18","author":"FK Swirski","year":"2018","unstructured":"Swirski FK, Nahrendorf M. Cardioimmunology: the immune system in cardiac homeostasis and disease [J]. Nat Rev Immunol. 2018;18(12):733\u201344. https:\/\/doi.org\/10.1038\/s41577-018-0065-8.","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"455_CR25","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1038\/s41577-018-0098-z","volume":"19","author":"PE Lazzerini","year":"2019","unstructured":"Lazzerini PE, Laghi-Pasini F, Boutjdir M, Capecchi PL. Cardioimmunology of arrhythmias: the role of autoimmune and inflammatory cardiac channelopathies [J]. Nat Rev Immunol. 2019;19(1):63\u20134. https:\/\/doi.org\/10.1038\/s41577-018-0098-z.","journal-title":"Nat Rev Immunol"},{"issue":"10","key":"455_CR26","doi-asserted-by":"publisher","first-page":"4876","DOI":"10.4049\/jimmunol.1200389","volume":"188","author":"ML Tarrio","year":"2012","unstructured":"Tarrio ML, Grabie N, Bu DX, et al. PD-1 protects against inflammation and myocyte damage in T cell-mediated myocarditis [J]. J Immunol. 2012;188(10):4876\u201384. https:\/\/doi.org\/10.4049\/jimmunol.1200389.","journal-title":"J Immunol"},{"issue":"4","key":"455_CR27","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1161\/CIRCULATIONAHA.121.056730","volume":"146","author":"H Zhu","year":"2022","unstructured":"Zhu H, Galdos FX, Lee D, et al. Identification of pathogenic immune cell subsets associated with checkpoint Inhibitor-Induced myocarditis [J]. Circulation. 2022;146(4):316\u201335. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.121.056730.","journal-title":"Circulation"},{"issue":"4","key":"455_CR28","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s11897-017-0343-y","volume":"14","author":"N Suthahar","year":"2017","unstructured":"Suthahar N, Meijers WC, Sillje HHW, de Boer RA. From inflammation to Fibrosis-Molecular and cellular mechanisms of myocardial tissue remodelling and perspectives on differential treatment opportunities [J]. Curr Heart Fail Rep. 2017;14(4):235\u201350. https:\/\/doi.org\/10.1007\/s11897-017-0343-y.","journal-title":"Curr Heart Fail Rep"},{"issue":"Suppl 4","key":"455_CR29","doi-asserted-by":"publisher","first-page":"iv39","DOI":"10.1093\/rheumatology\/kel315","volume":"45","author":"PM Seferovic","year":"2006","unstructured":"Seferovic PM, Ristic AD, Maksimovic R, et al. Cardiac arrhythmias and conduction disturbances in autoimmune rheumatic diseases [J]. Rheumatology (Oxford). 2006;45(Suppl 4):iv39\u201342. https:\/\/doi.org\/10.1093\/rheumatology\/kel315.","journal-title":"Rheumatology (Oxford)"},{"issue":"9","key":"455_CR30","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1038\/nrcardio.2017.61","volume":"14","author":"PE Lazzerini","year":"2017","unstructured":"Lazzerini PE, Capecchi PL, Laghi-Pasini F, Boutjdir M. Autoimmune channelopathies as a novel mechanism in cardiac arrhythmias [J]. Nat Rev Cardiol. 2017;14(9):521\u201335. https:\/\/doi.org\/10.1038\/nrcardio.2017.61.","journal-title":"Nat Rev Cardiol"},{"issue":"9","key":"455_CR31","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1002\/cac2.12320","volume":"42","author":"Y Xu","year":"2022","unstructured":"Xu Y, Song Y, Liu X, et al. Prediction of major adverse cardiac events is the first critical task in the management of immune checkpoint inhibitor-associated myocarditis [J]. Cancer Commun (Lond). 2022;42(9):902\u20135. https:\/\/doi.org\/10.1002\/cac2.12320.","journal-title":"Cancer Commun (Lond)"},{"key":"455_CR32","doi-asserted-by":"publisher","unstructured":"Puzanov I, Subramanian P, Yatsynovich YV, et al. Clinical characteristics, time course, treatment and outcomes of patients with immune checkpoint inhibitor-associated myocarditis. J Immunother Cancer. 2021;9(6). https:\/\/doi.org\/10.1136\/jitc-2021-002553.","DOI":"10.1136\/jitc-2021-002553"}],"container-title":["Cardio-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40959-026-00455-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40959-026-00455-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40959-026-00455-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T12:42:44Z","timestamp":1774615364000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40959-026-00455-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,20]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["455"],"URL":"https:\/\/doi.org\/10.1186\/s40959-026-00455-5","relation":{},"ISSN":["2057-3804"],"issn-type":[{"value":"2057-3804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,20]]},"assertion":[{"value":"20 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The ethics committee of Peking Union Medical College Hospital approved this study, and it followed the principles outlined in the Declaration of Helsinki. Written informed consent was obtained from participants or their legal representatives.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"42"}}